Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
The Journal of Family Practice|April 5, 2017
Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and GenericsEugene E Wright, Thomas C Blevins, Beverly Reed, et al.
Diabetes Technology & Therapeutics|February 1, 2026
Case Reports: Practical Use of Pulmonary Inhaled (Technosphere) Insulin in Type 1 Diabetes, Type 2 Diabetes, and PregnancyIrl B Hirsch, Thomas C Blevins, Amy M Valent, et al.
Diabetes Technology & Therapeutics|October 22, 2020
Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover StudyKerem Ozer, Alison M Cooper, Lily P Ahn, et al.
Diabetes, Obesity & Metabolism|November 7, 2019
Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch studyThomas C Blevins, Abhijit Barve, Yaron Raiter, et al.
Diabetes, Obesity & Metabolism|October 20, 2022
Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trialTadej Battelino, Thomas Danne, Steve V Edelman, et al.
Diabetes, Obesity & Metabolism|August 17, 2018
Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 studyThomas C Blevins, Abhijit Barve, Bin Sun, et al.
Diabetes Care|August 13, 2014
Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)John B Buse, Tina Vilsbøll, Jerry Thurman, et al.
Diabetes, Obesity & Metabolism|February 21, 2019
Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulinTina Vilsbøll, Thomas C Blevins, Esteban Jodar, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 17, 2022
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog<sup>®</sup>) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label StudyThomas C Blevins, Yaron Raiter, Bin Sun, et al.
Thyroid : Official Journal of the American Thyroid Association|May 10, 2014
Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodulesSylvie Beaudenon-Huibregtse, Erik K Alexander, Richard B Guttler, et al.
Pageof 3